Department of Neurosurgery, Consorcio Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Department of Neurosurgery, Consorcio Hospital General Universitario de Valencia, 46014 Valencia, Spain.
Neurocirugia (Astur : Engl Ed). 2022 Nov-Dec;33(6):350-355. doi: 10.1016/j.neucie.2021.06.007.
Central nervous system (CNS) involvement in the context of relapsed/refractory Hodgkin lymphoma (HL) is a quite rare, but well-known complication. Nevertheless, primary CNS-HL is an exceedingly rare condition, which diagnosis is based on well-defined morphological and immunohistochemical features, in addition to isolated involvement of the CNS. In spite of limited casuistry (just over twenty cases reported in the literature), available data agree that primary and isolated CNS-HL, when treated with a combination of surgery followed by some form of adjuvant therapy (radiotherapy±chemotherapy), carries a better prognosis than those cases with CNS involvement in the context of relapsed/refractory HL or those with CNS non-Hodgkin lymphoma. We herein report a case of a 55-year-old female patient who was diagnosed with primary CNS-HL. The patient was treated with complete surgical resection followed by intrathecal chemotherapy and whole brain radiotherapy (WBRT), showing fourteen months of disease-free survival at the time of this case report. A review of the available literature is also presented.
中枢神经系统(CNS)受累是复发/难治性霍奇金淋巴瘤(HL)的一种罕见但众所周知的并发症。然而,原发性中枢神经系统 HL 是一种极其罕见的疾病,其诊断基于明确的形态学和免疫组织化学特征,以及中枢神经系统的孤立受累。尽管病例数有限(文献中仅报道了二十多例),但现有数据表明,原发性和孤立性中枢神经系统 HL 通过手术联合辅助治疗(放疗±化疗)治疗,比复发/难治性 HL 中枢神经系统受累或中枢神经系统非霍奇金淋巴瘤患者的预后更好。本文报告了一例 55 岁女性患者,该患者被诊断为原发性中枢神经系统 HL。该患者接受了完全手术切除,随后进行了鞘内化疗和全脑放疗(WBRT),在本病例报告时,患者无疾病生存 14 个月。本文还对现有文献进行了回顾。